THE OBESE ASTHMA PHENOTYPE: CLINICAL CHALLENGES, MECHANISTIC INSIGHTS, AND PERSONALIZED MANAGEMENT STRATEGIES

Razikova I.S., Akromov A.T.
Republican Specialized Scientific and Practical Medical Center of Allergology and Clinical Immunology (Tashkent, Uzbekistan)
Tashkent State Medical University (Tashkent, Uzbekistan)

Abstract*. The syndemic of obesity and asthma represents a significant and growing global health challenge. A distinct "obese asthma" phenotype is now widely recognized, characterized by more severe disease, increased exacerbation frequency, and reduced responsiveness to standard inhaled corticosteroid (ICS) therapy. The pathophysiology is multifactorial, involving mechanical lung restriction, systemic metabolic inflammation driven by adipose-derived mediators, and distinct immunological pathways. This review synthesizes current evidence on the mechanisms linking obesity and asthma, explores the clinical implications for diagnosis and phenotyping, and evaluates contemporary management strategies. We emphasize that effective care requires moving beyond a one-size-fits-all approach. Future directions must include phenotyping-guided pharmacotherapy and the integration of structured weight management programs, supported by patient-centered communication models like shared decision-making, to improve outcomes in this complex patient population.*

Keywords: *Asthma, Obesity, Phenotype, Leptin, Adiponectin, Personalized Medicine, Shared Decision Making*

Introduction.

Asthma, a heterogeneous disease of chronic airway inflammation, affects over 300 million people globally. Parallel to the rise in asthma prevalence, obesity rates have reached epidemic proportions, creating a substantial overlap between these two conditions. Epidemiological studies have consistently demonstrated obesity as a major risk factor for the development and severity of asthma, with a clear dose-response relationship observed across diverse populations.

This association is not merely coincidental but reflects a complex pathobiological interaction. Patients with co-morbid obesity and asthma often present a unique clinical challenge: they experience poorer symptom control, higher healthcare utilization, and diminished quality of life compared to their non-obese counterparts. This review aims to dissect the pathophysiology of the obese asthma phenotype, outline its diagnostic challenges, and discuss the evolution of management strategies towards a more personalized, effective approach.

The Pathophysiological Interface of Obesity and Asthma

The mechanisms underpinning the obese asthma phenotype are broadly categorized into mechanical and inflammatory pathways, which often coexist and synergize.

1. Mechanical Restriction: Massive obesity, particularly with central adiposity, imposes a mechanical load on the respiratory system. It reduces functional residual capacity (FRC) and expiratory reserve volume, leading to breathing at low lung volumes. This state promotes airway hyperresponsiveness and predisposes to atelectasis, which can mimic or exacerbate asthma symptoms. The reduction in tidal volume also impacts the deposition and efficacy of inhaled medications.

2. Metabolic Inflammation and Adipokines: Adipose tissue, far from being inert, is an active endocrine organ. In obesity, hypertrophied adipocytes and infiltrating immune cells create a state of chronic, low-grade systemic inflammation.

- **Leptin:** This pro-inflammatory adipokine, elevated in obesity, can enhance TH2 and TH1 immune responses, promote airway smooth muscle proliferation, and potentially worsen bronchoconstriction.
- **Adiponectin:** In contrast to leptin, adiponectin has anti-inflammatory properties

and is decreased in obesity. Its reduction may remove a protective brake on airway inflammation.

• **Other Mediators:** Adipose tissue also overproduces cytokines such as IL-6, TNF-α, and PAI-1, which can spill over into the systemic circulation and prime the airways for heightened inflammatory responses.

Phenotyping Obese Asthma: Beyond a Single Disease

Current consensus identifies at least two primary phenotypes within the obese asthma spectrum, crucial for guiding therapy:

• **Early-Onset Allergic Asthma with Co-morbid Obesity:** This phenotype involves patients with classic, TH2-high childhood-onset asthma who subsequently become obese. Obesity exacerbates their pre-existing allergic airway disease, leading to worse control. Biomarkers may include elevated IgE, blood/sputum eosinophils, and FeNO.

• **Late-Onset Non-Allergic Asthma of Obesity:** This novel phenotype typically emerges in adulthood, predominantly in women, and is often non-atopic. It is characterized by a TH2-low inflammation profile (low eosinophils, normal FeNO) and appears to be driven more by innate immune activation and mechanical factors. This group demonstrates particularly poor response to standard ICS therapy.

Diagnostic Challenges in the Obese Asthmatic

Accurate diagnosis is paramount. The symptoms of dyspnea on exertion in an obese individual can be attributed to deconditioning, mechanical restriction, or cardiac comorbidity, leading to both over- and under-diagnosis of asthma.

• **Spirometry is Essential:** Objective confirmation with pre- and post-bronchodilator spirometry is critical. A reduced FEV1/FVC ratio with significant reversibility (≥12% and 200mL increase in FEV1) confirms asthma.

• **Pitfalls:** Restrictive patterns from obesity can confound interpretation. Body plethysmography may be needed to assess lung volumes. Furthermore, the negative predictive value of tests like methacholine challenge is high, helping to rule out asthma in symptomatic obese patients.

Management: Tailoring Therapy for the Phenotype

The traditional step-up approach for asthma management requires refinement for obese patients.

1. Pharmacotherapy:

• **Reduced ICS Response:** Multiple studies confirm that obese asthmatics, particularly those with the late-onset phenotype, have a blunted response to ICS.

• **Personalized Options:** For TH2-high obese asthma, biologics targeting IgE (Omalizumab), IL-5 (Mepolizumab, Reslizumab), or IL-4/IL-13 (Dupilumab) may be effective. For TH2-low patients, the focus may shift to long-acting muscarinic antagonists (LAMAs), weight loss, and management of co-morbidities.

• **Leukotriene Modifiers:** Some evidence suggests that leukotriene receptor antagonists (LTRAs) may be relatively more effective in obese asthmatics than ICS, possibly due to the involvement of leukotrienes in metabolic inflammation.

2. Non-Pharmacological Interventions:

• **Weight Loss:** This remains the most targeted intervention. Even a modest 5-10% weight loss can lead to significant improvements in asthma control, quality of life, lung function, and reduction in exacerbations. Strategies include:

  ○ **Lifestyle Modification:** Diet and exercise programs.

  ○ **Bariatric Surgery:** Produces the most dramatic and sustained weight loss and has been shown to lead to asthma remission or marked improvement in a majority of severely obese patients.

• **Exercise:** Beyond promoting weight loss, regular exercise has independent anti-inflammatory benefits and can improve cardiopulmonary fitness and symptom perception.

The Role of Shared Decision-Making (SDM)

Managing a complex chronic condition like obese asthma requires a strong therapeutic alliance. SDM is a collaborative process where clinicians and patients work together to select treatments based on clinical evidence and patient preferences, values, and context.

For the obese asthmatic, SDM can be used to:

• Discuss the specific link between their weight and asthma symptoms.

• Set realistic, shared goals for weight management and asthma control.

• Choose controller medications, weighing the evidence for efficacy in their likely phenotype.

• Develop a personalized asthma action plan that incorporates weight management strategies.

Evidence, including from the Asthma Comparative Effectiveness (ACE) study, suggests that SDM improves medication adherence, reduces acute care visits, and enhances quality of life across all BMI categories, making it a vital tool for engaging obese patients in their care.

Conclusion and Future Directions.

Obesity modifies the presentation, pathophysiology, and treatment response of asthma. Recognizing the obese asthma phenotype is a critical first step towards personalized medicine. Future management must be multifaceted:

1. **Accurate Phenotyping:** Utilize biomarkers (eosinophils, FeNO) to guide therapy.

2. **Aggressive Weight Management:** Integrate weight loss as a core component of the asthma treatment plan.

3. **Phenotype-Guided Pharmacotherapy:** Select medications based on the underlying inflammatory endotype rather than a generic protocol.

4. **Embrace Patient-Centered Care:** Utilize SDM to overcome barriers and improve adherence.

By adopting this comprehensive and personalized approach, clinicians can significantly improve the challenging outcomes historically associated with the coexistence of obesity and asthma.

REFERENCES

1. Lingvay I., Cohen R.V., Roux C.W., Sumithran P. Obesity in adults. Lancet. 2024; 7 (404): 972–987.

2. García-García F.J., Monistrol-Mula A., Cardellach F., et al. Nutrition, Bioenergetics, and Metabolic Syndrome. Nutrients. 2020; 12 (9): 2785.

3. Julia V., Macia L., Dombrowicz D. The Impact of Diet on Asthma and Allergic Diseases. Nat. Rev. Immunol. 2015; 15 (5): 308–322.

4. Guo C., Liu P., Lin K., et al. Nutritional supplement therapy improves oxidative stress, immune response, pulmonary function, and quality of life in allergic asthma patients: an open-label pilot study. Altern. Med. Rev. 2012; 17 (1): 42–56.

5. Scott H.A., Ng S.H., McLoughlin R.F., et al. Effect obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis. Thorax. 2023; 78 (10): 957–965.

6. Fu J., McDonald V., Baines K.J., et al. Airway IL-1β and Systemic Inflammation as Predictors of Future Exacerbation Risk in Asthma and COPD. Chest. 2015; 148 (3): 618–629.

8. Micha R., Khatibzadeh S., Shi P., et al. Global, regional and national consumption of major food groups in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys worldwide. BMJ Open. 2015; 5 (9): e008705.

9. Wood L.G., Shivappa N., Berthon B.S., et al. Dietary Inflammatory Index is Related to Asthma Risk, Lung Function and Systemic Inflammation in Asthma. Clin. Exp. Allergy. 20 15; 45 (1): 177–183.

10. Konieczna J., Romaguera D., Pereira V., et al. Longitudinal association of changes in diet with changes in body weight and waist circumference in subjects at high cardiovascular risk: the PREDIMED trial. Int. J. Behav. Nutr. Phys. Act. 2019; 16 (1): 139.

11. Schwingshackl L., Morze J., Hoffmann G. Mediterranean diet and health status: Active ingredients and pharmacological mechanisms. Br. J. Pharmacol. 2020; 177 (6): 12 41–1257.

12. Dominguez L.J., Veronese N., Di Bella G., et al. Mediterranean diet in the management and prevention of obesity. Exp. Gerontol. 2023; 174: 112121.

13. Guilleminault L., Williams E., Scott H., et al. Diet and Asthma: Is It Time to Adapt Our Message? Nutrients. 2017; 9 (11): 1227.